Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanne Stowasser

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Drug Design, Development and Therapy|December 31, 2015
Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanibFrancesco Bonella, Susanne Stowasser, Lutz Wollin
CPT: Pharmacometrics & Systems Pharmacology|January 11, 2020
Parametric Time-to-Event Model for Acute Exacerbations in Idiopathic Pulmonary FibrosisFei Tang, Benjamin Weber, Susanne Stowasser, et al.
Frontiers in Pharmacology|February 17, 2022
Challenges for Clinical Drug Development in Pulmonary FibrosisEric S White, Matthew Thomas, Susanne Stowasser, et al.
The European Respiratory Journal|October 2, 2015
Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature reviewGanesh Raghu, Valeria C Amatto, Jürgen Behr, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 21, 2025
Exposure-Efficacy Meta-Model of Nintedanib in Adult Patients With Chronic Fibrosing Interstitial Lung DiseasesSonja Hartmann, Julie Janssen, Jakob Ribbing, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|March 1, 2019
Fibrosing interstitial lung diseases: knowns and unknownsVincent Cottin, Lutz Wollin, Aryeh Fischer, et al.
Respiratory Research|January 8, 2020
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programmeClaudia Valenzuela, Sebastiano Emanuele Torrisi, Nicolas Kahn, et al.
BMC Pulmonary Medicine|January 14, 2016
Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain--results of a Delphi PanelFerran Morell, Dirk Esser, Jonathan Lim, et al.
Lung|July 6, 2016
First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted ValueWim A Wuyts, Martin Kolb, Susanne Stowasser, et al.
American Journal of Respiratory and Critical Care Medicine|September 23, 2015
Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSISUlrich Costabel, Yoshikazu Inoue, Luca Richeldi, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Drug Design, Development and Therapy|December 31, 2015
Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanibFrancesco Bonella, Susanne Stowasser, Lutz Wollin
CPT: Pharmacometrics & Systems Pharmacology|January 11, 2020
Parametric Time-to-Event Model for Acute Exacerbations in Idiopathic Pulmonary FibrosisFei Tang, Benjamin Weber, Susanne Stowasser, et al.
Frontiers in Pharmacology|February 17, 2022
Challenges for Clinical Drug Development in Pulmonary FibrosisEric S White, Matthew Thomas, Susanne Stowasser, et al.
The European Respiratory Journal|October 2, 2015
Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature reviewGanesh Raghu, Valeria C Amatto, Jürgen Behr, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 21, 2025
Exposure-Efficacy Meta-Model of Nintedanib in Adult Patients With Chronic Fibrosing Interstitial Lung DiseasesSonja Hartmann, Julie Janssen, Jakob Ribbing, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|March 1, 2019
Fibrosing interstitial lung diseases: knowns and unknownsVincent Cottin, Lutz Wollin, Aryeh Fischer, et al.
Respiratory Research|January 8, 2020
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programmeClaudia Valenzuela, Sebastiano Emanuele Torrisi, Nicolas Kahn, et al.
BMC Pulmonary Medicine|January 14, 2016
Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain--results of a Delphi PanelFerran Morell, Dirk Esser, Jonathan Lim, et al.
Lung|July 6, 2016
First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted ValueWim A Wuyts, Martin Kolb, Susanne Stowasser, et al.
American Journal of Respiratory and Critical Care Medicine|September 23, 2015
Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSISUlrich Costabel, Yoshikazu Inoue, Luca Richeldi, et al.
Pageof 7